Bioresorbable scaffolds for treatment of coronary bifurcation lesions: Critical appraisal and future perspectives
Corresponding Author
Roberto Diletti MD
Department of Interventional Cardiology, Thoraxcenter Erasmus MC, Rotterdam, the Netherlands
Correspondence to: Roberto Diletti MD, Interventional Cardiology Department, Erasmus MC, 's-Gravendijkwal 230, 3015 CE Rotterdam, the Netherlands. E-mail: [email protected]Search for more papers by this authorDidier Tchetche MD
Department of Interventional Cardiology, Clinique Pasteur, Toulouse, France
Search for more papers by this authorEmanuele Barbato MD, PhD
Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium
Search for more papers by this authorAzeem Latib MD
Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy
Interventional Cardiology Unit, EMO-GVM Centro Cuore Columbus, Milan, Italy
Search for more papers by this authorBruno Farah MD
Department of Interventional Cardiology, Clinique Pasteur, Toulouse, France
Search for more papers by this authorRobert-Jan van Geuns MD, PhD
Department of Interventional Cardiology, Thoraxcenter Erasmus MC, Rotterdam, the Netherlands
Search for more papers by this authorAntonio Colombo MD
Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy
Interventional Cardiology Unit, EMO-GVM Centro Cuore Columbus, Milan, Italy
Search for more papers by this authorJean Fajadet MD
Department of Interventional Cardiology, Clinique Pasteur, Toulouse, France
Search for more papers by this authorNicolas M. van Mieghem MD, PhD
Department of Interventional Cardiology, Thoraxcenter Erasmus MC, Rotterdam, the Netherlands
Search for more papers by this authorCorresponding Author
Roberto Diletti MD
Department of Interventional Cardiology, Thoraxcenter Erasmus MC, Rotterdam, the Netherlands
Correspondence to: Roberto Diletti MD, Interventional Cardiology Department, Erasmus MC, 's-Gravendijkwal 230, 3015 CE Rotterdam, the Netherlands. E-mail: [email protected]Search for more papers by this authorDidier Tchetche MD
Department of Interventional Cardiology, Clinique Pasteur, Toulouse, France
Search for more papers by this authorEmanuele Barbato MD, PhD
Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium
Search for more papers by this authorAzeem Latib MD
Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy
Interventional Cardiology Unit, EMO-GVM Centro Cuore Columbus, Milan, Italy
Search for more papers by this authorBruno Farah MD
Department of Interventional Cardiology, Clinique Pasteur, Toulouse, France
Search for more papers by this authorRobert-Jan van Geuns MD, PhD
Department of Interventional Cardiology, Thoraxcenter Erasmus MC, Rotterdam, the Netherlands
Search for more papers by this authorAntonio Colombo MD
Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy
Interventional Cardiology Unit, EMO-GVM Centro Cuore Columbus, Milan, Italy
Search for more papers by this authorJean Fajadet MD
Department of Interventional Cardiology, Clinique Pasteur, Toulouse, France
Search for more papers by this authorNicolas M. van Mieghem MD, PhD
Department of Interventional Cardiology, Thoraxcenter Erasmus MC, Rotterdam, the Netherlands
Search for more papers by this authorConflict of interest: Nothing to report.
Abstract
Bioresorbable vascular scaffolds have been recently introduced as a novel paradigm for coronary artery disease treatment allowing temporary vessel support and drug delivery without indefinite coronary caging, potentially reducing the long-term limitation of metallic stents. The scientific community has rapidly embraced this concept and bioresorbable devices have been introduced in clinical practice. However, despite the fact that bifurcation lesions represent a large and challenging subset in the field of interventional cardiology, this subgroup of lesions have been avoided in the initial experience with bioresorbable scaffolds and clear recommendations on methodological approaches are lacking. In the present report, we describe the various techniques for bifurcation treatment with bioresorbable scaffolds and the theoretical advantages and disadvantages of this technology in different scenarios, with a glimpse to challenging subsets and possible complications. Therefore, we aim to provide experience based insights and practical guidance for bioresorbable scaffold implantation in bifurcation lesions. © 2016 Wiley Periodicals, Inc.
REFERENCES
- 1Lassen JF, Holm NR, Stankovic G, Lefevre T, Chieffo A, Hildick-Smith D, Pan M, Darremont O, Albiero R Ferenc M, et al. Percutaneous coronary intervention for coronary bifurcation disease: Consensus from the first 10 years of the European Bifurcation Club meetings. EuroIntervention 2014; 10: 545–560.
- 2Diletti R, Garcia-Garcia HM, Bourantas CV, van Geuns RJ, Van Mieghem NM, Vranckx P, Zhang YJ, Farooq V, Iqbal J Wykrzykowska JJ, et al. Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: Insights from the RESOLUTE All Comers Trial. Heart 2013; 99: 1267–1274.
- 3Al Suwaidi J, Berger PB, Rihal CS, Garratt KN, Bell MR, Ting HH, Bresnahan JF, Grill DE, Holmes DR Jr. Immediate and long-term outcome of intracoronary stent implantation for true bifurcation lesions. J Am Coll Cardiol 2000; 35: 929–936.
- 4Colombo A, Al-Lamee R. Bifurcation lesions: An inside view. Circ Cardiovasc Interv 2010; 3: 94–96.
- 5Colombo A, Moses JW, Morice MC, Ludwig J, Holmes DR Jr, Spanos V, Louvard Y, Desmedt B, Di Mario C, Leon MB. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 2004; 109: 1244–1249.
- 6Farb A, Boam AB. Stent thrombosis redux—The FDA perspective. N Engl J Med 2007; 356: 984–987.
- 7Farb A, Burke AP, Kolodgie FD, Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 2003; 108: 1701–1706.
- 8Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J 2012; 33: 16–25.
- 9Colombo A, Bramucci E, Sacca S, Violini R, Lettieri C, Zanini R, Sheiban I, Paloscia L, Grube E Schofer J, et al. Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study. Circulation 2009; 119: 71–78.
- 10Louvard Y, Thomas M, Dzavik V, Hildick-Smith D, Galassi AR, Pan M, Burzotta F, Zelizko M, Dudek D Ludman P, et al. Classification of coronary artery bifurcation lesions and treatments: Time for a consensus! Catheter Cardiovasc Interv 2008; 71: 175–83.
- 11Murray CD. The physiological principle of minimum work applied to the angle of branching of arteries. J Gen Physiol 1926; 9: 835–841.
- 12Finet G, Gilard M, Perrenot B, Rioufol G, Motreff P, Gavit L, Prost R. Fractal geometry of arterial coronary bifurcations: A quantitative coronary angiography and intravascular ultrasound analysis. EuroIntervention 2008; 3: 490–498.
- 13Kamiya A, Togawa T. Optimal branching structure of the vascular tree. Bull Math Biophys 1972; 34: 431–438.
- 14Huo Y, Finet G, Lefevre T, Louvard Y, Moussa I, Kassab GS. Optimal diameter of diseased bifurcation segment: A practical rule for percutaneous coronary intervention. EuroIntervention 2012; 7: 1310–1316.
- 15Gomez-Lara J, Diletti R, Brugaletta S, Onuma Y, Farooq V, Thuesen L, McClean D, Koolen J, Ormiston JA Windecker S, et al. Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: An ABSORB cohort B trial sub-study. EuroIntervention 2012; 8: 214–224.
- 16Diletti R, Onuma Y, Farooq V, Gomez-Lara J, Brugaletta S, van Geuns RJ, Regar E, de Bruyne B, Dudek D Thuesen L, et al. 6-Month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mm. J Am Coll Cardiol 2011; 58: 258–264.
- 17Diletti R, Farooq V, Girasis C, Bourantas C, Onuma Y, Heo JH, Gogas BD, van Geuns RJ, Regar E de Bruyne B, et al. Clinical intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial. Heart 2013; 99: 98–105.
- 18Hildick-Smith D, Lassen JF, Albiero R, Lefevre T, Darremont O, Pan M, Ferenc M, Stankovic G, Louvard Y, European Bifurcation C. Consensus from the 5th European Bifurcation Club meeting. EuroIntervention 2010; 6: 34–38.
- 19van Geuns RJ, Gogas BD, Farooq V, Regar E, Serruys PW. 3-Dimensional reconstruction of a bifurcation lesion with double wire after implantation of a second generation everolimus-eluting bioresorbable vascular scaffold. Int J Cardiol 2011; 153: e43–e45.
- 20Ormiston JA, Webber B, Ubod B, Webster MW, White J. Absorb everolimus-eluting bioresorbable scaffolds in coronary bifurcations: a bench study of deployment, side branch dilatation and post-dilatation strategies. EuroIntervention 2015.; 10: 1169–1177.
- 21Di Mario C, Foin N, Colombo A. Kissing vanishing stents: Are we trading ephemeral benefit for permanent damage? EuroIntervention 2013; 9: 777–779.
- 22Seth A, Sengottuvelu G, Ravisekar V. Salvage of side branch by provisional “TAP technique” using Absorb bioresorbable vascular scaffolds for bifurcation lesions: first case reports with technical considerations. Catheter Cardiovasc Interv 2014; 84: 55–61.
- 23Ruzsa Z, van der Linden M, Van Mieghem NM, Regar E, Ligthart JM, Serruys P, van Geuns RJ. Culotte stenting with bioabsorbable everolimus-eluting stents. Int J Cardiol 2013; 168: e35–e37.
- 24Dzavik V, Colombo A. The absorb bioresorbable vascular scaffold in coronary bifurcations: Insights from bench testing. JACC Cardiovasc Interv 2014; 7: 81–88.
- 25van Mieghem N, Wilschut JJ, Ligthart J, Witberg K, van Geuns RJ, Regar E. Modified T-technique with bioresorbable scaffolds ensures complete carina coverage, an optical coherence tomography study. JACC Cardiovasc Interv 2014; 7: e109–e110.
- 26Iakovou I, Ge L, Colombo A. Contemporary stent treatment of coronary bifurcations. J Am Coll Cardiol 2005; 46: 1446–1455.
- 27Sharma SK, Choudhury A, Lee J, Kim MC, Fisher E, Steinheimer AM, Kini AS. Simultaneous kissing stents (SKS) technique for treating bifurcation lesions in medium-to-large size coronary arteries. Am J Cardiol 2004; 94: 913–917.
- 28Koo BK, Waseda K, Kang HJ, Kim HS, Nam CW, Hur SH, Kim JS, Choi D, Jang Y Hahn JY, et al. Anatomic and functional evaluation of bifurcation lesions undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 2010; 3: 113–119.
- 29Di Mario C, Iakovou I, van der Giessen WJ, Foin N, Adrianssens T, Tyczynski P, Ghilencea L, Viceconte N, Lindsay AC. Optical coherence tomography for guidance in bifurcation lesion treatment. EuroIntervention 2010; 6: J99–J106.
- 30Diletti R, Garcia-Garcia HM, Gomez-Lara J, Brugaletta S, Wykrzykowska JJ, van Ditzhuijzen N, van Geuns RJ, Regar E, Ambrosio G, Serruys PW. Assessment of coronary atherosclerosis progression and regression at bifurcations using combined IVUS and OCT. JACC Cardiovasc Imaging 2011; 4: 774–80.
- 31Okamura T, Onuma Y, Garcia-Garcia HM, Regar E, Wykrzykowska JJ, Koolen J, Thuesen L, Windecker S, Whitbourn R McClean DR, et al. 3-Dimensional optical coherence tomography assessment of jailed side branches by bioresorbable vascular scaffolds. A Proposal for Classification. JACC Cardiovasc Interv 2010; 3: 836–844.
- 32Alegria-Barrero E, Foin N, Chan PH, Syrseloudis D, Lindsay AC, Dimopolous K, Alonso-Gonzalez R, Viceconte N, De Silva R, Di Mario C. Optical coherence tomography for guidance of distal cell recrossing in bifurcation stenting: choosing the right cell matters. EuroIntervention 2012; 8: 205–213.
- 33Farooq V, Gogas BD, Okamura T, Heo JH, Magro M, Gomez-Lara J, Onuma Y, Radu MD, Brugaletta S van Bochove G, et al. Three-dimensional optical frequency domain imaging in conventional percutaneous coronary intervention: The potential for clinical application. Eur Heart J 2013; 34: 875–885.
- 34Karanasos A, Tu S, van Ditzhuijzen NS, Ligthart JM, Witberg K, Van Mieghem N, van Geuns RJ, de Jaegere P, Zijlstra F Reiber JH, et al. A novel method to assess coronary artery bifurcations by OCT: Cut-plane analysis for side-branch ostial assessment from a main-vessel pullback. Eur Heart J Cardiovasc Imaging 2015; 16: 177–189.
- 35Grundeken MJ, Kraak RP, de Bruin DM, Wykrzykowska JJ. Three-dimensional optical coherence tomography evaluation of a left main bifurcation lesion treated with ABSORB(R) bioresorbable vascular scaffold including fenestration and dilatation of the side branch. Int J Cardiol 2013; 168: e107–e108.
- 36Sato K, Latib A, Panoulas VF, Naganuma T, Miyazaki T, Colombo A. A case of true left main bifurcation treated with bioresorbable everolimus-eluting stent v-stenting. JACC Cardiovasc Interv 2014; 7: e103–e104.
- 37Sengottuvelu G, Dattagupta A. Optical coherence tomographic image of dynamic left main coronary artery compression caused by intramural haematoma due to spontaneous coronary artery dissection - degloved artery managed with bioresorbable vascular scaffold. EuroIntervention 2015; 11: 659.
- 38Miyazaki T, Panoulas VF, Sato K, Naganuma T, Latib A, Colombo A. Bioresorbable vascular scaffolds for left main lesions; a novel strategy to overcome limitations. Int J Cardiol 2014; 175: e11–e13.
- 39Verheye S, Ormiston JA, Stewart J, Webster M, Sanidas E, Costa R, Costa JR Jr, Chamie D, Abizaid AS Pinto I, et al. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. JACC Cardiovasc Interv 2014; 7: 89–99.
- 40Muramatsu T, Onuma Y, Garcia-Garcia HM, Farooq V, Bourantas CV, Morel MA, Li X, Veldhof S, Bartorelli A Whitbourn R, et al. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: An interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials. JACC Cardiovasc Interv 2013; 6: 247–257.
- 41Onuma Y, Serruys PW, Muramatsu T, Nakatani S, van Geuns RJ, de Bruyne B, Dudek D, Christiansen E, Smits PC Chevalier B, et al. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2014; 7: 1400–1411.
- 42Okamura T, Serruys PW Regar E. Cardiovascular flashlight. The fate of bioresorbable struts located at a side branch ostium: serial three-dimensional optical coherence tomography assessment. Eur Heart J 2010; 31: 2179
- 43Karanasos A, Simsek C, Gnanadesigan M, van Ditzhuijzen NS, Freire R, Dijkstra J, Tu S, Van Mieghem N, van Soest G de Jaegere P, et al. OCT assessment of the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold. J Am Coll Cardiol 2014; 64: 2343–2356.